Grom Social Enterprises, Inc.: Nasdaq/NYSE listing notice — Grom Social receives Nasdaq deficiency notice for failing to meet $1.00 minimum bid price

Grom Social Enterprises, Inc.

Received deficiency letter on April 10, 2023 from Nasdaq listing qualifications department.
Common stock bid price below $1.00 for 30 consecutive business days; fails Listing Rule 5550(a)(2).
Initial compliance period ends October 9, 2023; cure by closing at or above $1.00 for 10 consecutive days.
Possible second 180-day period if company meets other listing standards and intends to cure via reverse split.
No assurance of regaining compliance; delisting could lead to trading on OTC Markets.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Grom Social Enterprises, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 10, 2023, Grom Social Enterprises, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minim

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001683168-23-002401

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.